Daiichi Sankyo, Inc., the U.S. subsidiary of Daiichi Sankyo Company, Ltd., will establish a new U.S. headquarters, co-locating its commercial and development divisions in Basking Ridge, New Jersey. The move is part of an ongoing effort to realize efficiencies and continue collaboration between the business segments, enabling innovation in its existing and emerging therapeutic areas such as cardiology, oncology, pain and other areas where there are unmet medical needs.

"Uniting our New Jersey-based personnel into a single location not only makes us more efficient, but it will also further strengthen collaboration among teams working across the entire life cycle of our medicines," said Glenn Gormley, M.D., Ph.D., chairman of the Board and president, Daiichi Sankyo, Inc. 

Daiichi Sankyo, Inc. is comprised of U.S.-based development functions, currently located in Edison, New Jersey, as well as all U.S. commercial departments, currently located in Parsippany, New Jersey.  The company expects to begin moving employees to the new location in 2017.

Daiichi Sankyo has over 100 years of scientific expertise and a presence in more than 20 countries, including 16,000 employees around the world.